TY - JOUR
T1 - LACE-Bio
T2 - Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer
AU - Seymour, Lesley
AU - Le Teuff, Gwénaël
AU - Brambilla, Elisabeth
AU - Shepherd, Frances A.
AU - Soria, Jean Charles
AU - Kratzke, Robert
AU - Graziano, Stephen
AU - Douillard, Jean Yves
AU - Rosell, Rafael
AU - Reiman, Anthony
AU - Lacas, Benjamin
AU - Lueza, Beranger
AU - Aviel-Ronen, Sarit
AU - McLeer, Anne
AU - Le Chevalier, Thierry
AU - Pirker, Robert
AU - Filipits, Martin
AU - Dunant, Ariane
AU - Pignon, Jean Pierre
AU - Tsao, Ming Sound
N1 - Publisher Copyright: © 2018 Elsevier Inc.
PY - 2019/3
Y1 - 2019/3
N2 - There are no validated molecular tools to allow patient selection for adjuvant chemotherapy after complete resection of non–small-cell lung cancer. Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. The majority of the promising biomarkers could not be validated, and none were predictive of benefit. Immunohistochemistry assays from single trials may be misleading. Background: Complete resection of non–small-cell lung cancer (NSCLC) offers the potential for cure after surgery and adjuvant chemotherapy. Patients may not benefit and may experience severe toxicity. There are no validated molecular tools to allow better patient selection. Materials and Methods: The LACE-Bio (LACE [Lung Adjuvant Cisplatin Evaluation]) project includes 4 trials (International Adjuvant Lung Cancer Trial [IALT], Adjuvant Navelbine International Trialist Association [ANITA], JBR10, and Cancer and Leukemia Group B (CALGB)-9633). Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. Results: The majority of the promising biomarkers could not be validated; the prognostic effect of tumor infiltrating lymphocytes and β-tubulin was confirmed. Potential causes include tissue fixation, storage, the use of tissue microarrays, and varying reagent/antibody batches. Conclusions: Immunohistochemistry assays from single trials may be misleading and require validation before being used for patient selection. LACE-Bio-2 is evaluating potential genomic biomarkers that may allow more precise selection of patients with NSCLC for adjuvant chemotherapy in NSCLC.
AB - There are no validated molecular tools to allow patient selection for adjuvant chemotherapy after complete resection of non–small-cell lung cancer. Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. The majority of the promising biomarkers could not be validated, and none were predictive of benefit. Immunohistochemistry assays from single trials may be misleading. Background: Complete resection of non–small-cell lung cancer (NSCLC) offers the potential for cure after surgery and adjuvant chemotherapy. Patients may not benefit and may experience severe toxicity. There are no validated molecular tools to allow better patient selection. Materials and Methods: The LACE-Bio (LACE [Lung Adjuvant Cisplatin Evaluation]) project includes 4 trials (International Adjuvant Lung Cancer Trial [IALT], Adjuvant Navelbine International Trialist Association [ANITA], JBR10, and Cancer and Leukemia Group B (CALGB)-9633). Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. Results: The majority of the promising biomarkers could not be validated; the prognostic effect of tumor infiltrating lymphocytes and β-tubulin was confirmed. Potential causes include tissue fixation, storage, the use of tissue microarrays, and varying reagent/antibody batches. Conclusions: Immunohistochemistry assays from single trials may be misleading and require validation before being used for patient selection. LACE-Bio-2 is evaluating potential genomic biomarkers that may allow more precise selection of patients with NSCLC for adjuvant chemotherapy in NSCLC.
KW - Adjuvant chemotherapy
KW - Biomarkers
KW - NSCLC
KW - Predicative
KW - Prognostic
UR - http://www.scopus.com/inward/record.url?scp=85055967423&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.cllc.2018.10.001
DO - https://doi.org/10.1016/j.cllc.2018.10.001
M3 - مقالة
C2 - 30414783
SN - 1525-7304
VL - 20
SP - 66-73.e6
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
IS - 2
ER -